| Literature DB >> 12469329 |
Lisa L von Moltke1, James L Weemhoff, Michael D Perloff, Leah M Hesse, Jerold S Harmatz, Barbara F Roth-Schechter, David J Greenblatt.
Abstract
The influence of high concentrations of zolpidem (100 microM, corresponding to approximately 200 times maximum therapeutic concentrations) on the activity of six human Cytochrome P450 (CYP) enzymes was evaluated in a model system using human liver microsomes. Zolpidem produced negligible or weak inhibition of human CYP1A2, 2B6, 2C9, 2C19, 2D6, and 3A. Transport of rhodamine 123, presumed to be mediated mainly by the energy-dependent efflux transport protein P-glycoprotein, was studied in a cell culture system using a human intestinal cell line. High concentrations of zolpidem (100 microM), exceeding the usual therapeutic range by more than 100-fold, produced only modest impairment of rhodamine 123 transport. The findings indicate that zolpidem is very unlikely to cause clinical drug interactions attributable to impairment of CYP activity or P-gp mediated transport. Copyright 2002 John Wiley & Sons, Ltd.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12469329 DOI: 10.1002/bdd.329
Source DB: PubMed Journal: Biopharm Drug Dispos ISSN: 0142-2782 Impact factor: 1.627